首页|Hospital Arnau de Vilanova Reports Findings in Atrial Fibrillation (Oral anticoa gulant treatment in atrial fibrillation: The AFIRMA real-world study using natur al language processing and machine learning)
Hospital Arnau de Vilanova Reports Findings in Atrial Fibrillation (Oral anticoa gulant treatment in atrial fibrillation: The AFIRMA real-world study using natur al language processing and machine learning)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News-New research on Heart Disorders and Di seases - Atrial Fibrillation is the subject of a report. According to news repor ting out of Valencia, Spain, by NewsRx editors, research stated, "Oral anticoagu lation (OAC) is key in atrial fibrillation (AF) thromboprophylaxis, but Spain la cks substantial real-world evidence. We aimed to analyze the prevalence, clinica l characteristics, and treatment patterns among patients with AF undertaking OAC , using natural language processing (NLP) and machine learning (ML)." Our news journalists obtained a quote from the research from Hospital Arnau de V ilanova, "This retrospective study included AF patients on OAC from 15 Spanish h ospitals (2014-2020). Using EHRead®(including NLP and ML), and SNOMED_ CT, we extracted and analyzed patient demographics, comorbidities, and OAC treat ment from electronic health records. AF prevalence was estimated, and a descript ive analysis was conducted. Among 4,664,224 patients in our cohort, AF prevalenc e ranged from 1.9% to 2.9%. A total of 57,190 patient s on OAC therapy were included, 80.7% receiving Vitamin K antagoni sts (VKA) and 19.3% Direct-acting OAC (DOAC). The median age was 7 8 and 76 years respectively, with males constituting 53% of the co hort. Comorbidities like hypertension (76.3%), diabetes (48.0% ), heart failure (42.2%), and renal disease (18.7%) we re common, and more frequent in VKA users. Over 50% had a high CHA 2DS2-VASc score. The most frequent treatment switch was from DOAC to acenocoumar ol (58.6% to 70.2%). In switches from VKA to DOAC, ap ixaban was the most chosen (35.2%). Utilizing NLP and ML to extract RWD, we established the most comprehensive Spanish cohort of AF patients with O AC to date. Analysis revealed a high AF prevalence, patient complexity, and a ma rked VKA preference over DOAC."
ValenciaSpainEuropeAnticoagulantsAtrial FibrillationCardiac ArrhythmiasCyborgsDrugs and TherapiesEmergin g TechnologiesHealth and MedicineHeart DiseaseHeart Disorders and DiseasesHematologic AgentsMachine LearningNatural Language Processing
NETL
NSTL
